Focused on the

discovery, design,

& development

SCROLL

of innovative

peptide-based

medicines

SCROLL

for people

who need them

SCROLL
  • Share price information

    ZEAL (COP)

    864.00DKK

    Zealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL.

    More Stock information
  • Annual report 2023

    ZPAR23 Fullpage Images Firefly Copy

    Read Zealand Pharma's latest annual report.

    Download PDF
  • Corporate presentation

    Crosby CHI NJ USA JW 0875 B3A6034

    See Zealand Pharma's latest Corporate Presentation for an overview of our R&D pipeline and additional company information.

    Download PDF

Latest news

View all news
  • COMPANY ANNOUNCEMENT

    Zealand Pharma major shareholder announcement: Van Herk Investments

    READ MORE
  • COMPANY ANNOUNCEMENT

    Total number of shares and voting rights in Zealand Pharma at June 28, 2024

    READ MORE
  • COMPANY ANNOUNCEMENT

    Zealand Pharma completes registration of capital increase

    READ MORE
  • COMPANY ANNOUNCEMENT

    Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion

    READ MORE

Innovating across a range of disease areas

Obesity

Crowd 1

As one of the greatest healthcare challenges of our time, obesity and overweight are associated with more than 220 complications and co-morbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation. Zealand Pharma is working to address this chronic disease with differentiated product candidates.

Read more

Rare diseases

1600Px COLOURBOX31315294

Severely impacting quality of life, many rare diseases represent major unmet needs. Zealand Pharma has a long-standing commitment to people living with congenital hyperinsulinism (CHI) and short bowel syndrome (SBS).

Congenital hyperinsulinism Short Bowel Syndrome

Chronic inflammation

Zealand Pharma 1102

Through damage to tissues and organs, chronic inflammation can lead to the development of a broad range of potentially disabling or life-threatening illnesses. Zealand Pharma believes peptide medicines present opportunities for innovation in the treatment of chronic inflammatory diseases. 

Read more

Type 1 diabetes

ZEALAND AR 2018 Anders0829 B3A5770

Despite advances in insulin chemistry and delivery systems, achieving tight control over blood-glucose levels remains a daily challenge for those living with type 1 diabetes, increasing the risk of diabetes complications. Zealand Pharma aspires to improve type 1 diabetes management.

Read more
Crowd 1 1600Px COLOURBOX31315294 Zealand Pharma 1102 ZEALAND AR 2018 Anders0829 B3A5770
Illustration Accordion 1 Grey

An innovative R&D pipeline

Obesity

Petrelintide

A long-acting amylin analog as a weight-loss medication representing an alternative to GLP-1 receptor agonists.

Obesity

Dapiglutide

A long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation.

Obesity

Survodutide

A long-acting glucagon/GLP-1 receptor dual agonist targeting obesity and MASH licensed to Boehringer Ingelheim.

Obesity

ZP6590

A GIP receptor agonist targeting obesity as a potential complement to GLP-1 for increased effect and/or tolerability.

Congenital Hyperinsulinism

Dasiglucagon: Continuous infusion

A glucagon analog designed to allow for continuous subcutaneous infusion via a wearable pump system for the treatment of Congenital Hyperinsulinism (CHI).

Short Bowel Syndrome

Glepaglutide

A long-acting GLP-2 analog designed to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure.

Chronic inflammation

ZP9830

A potent and selective blocker of the Kv1.3 ion channel with the potential to treat a broad range of T-cell-driven autoimmune diseases.

Chronic inflammation

ZP10068

A long-acting inhibitor of the Complement C3 protein with the potential to target a broad range of complement-mediated diseases.

Type 1 diabetes

Dasiglucagon: Diabetes

A glucagon analog with potential for use in Bihormonal Pancreas systems with insulin for the treatment of Type 1 diabetes

Safety, tolerability, and clinical effects of ZP8396, an amylin analog

Featured publication

Results from a 6-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in October 2024.

  • Read more
  • All scientific publications
  • Zealand Pharma 0682

    Fostering an enriching workplace

    At Zealand, we promote engagement, growth, diversity and inclusion. We believe that engaged and motivated employees with a passion for making a difference bring a positive mindset and inspiring level of energy to work. Our highly skilled employees are at the center of the medical treatment options that we design and develop for patients. We pride ourselves on our ability to work together as one team and to foster a strong and engaging company culture founded on collaboration, courage, empowerment, and trust.

  • Careers at zealand
  • Current Opportunities
  • Zealand Pharm Office Part 2 BF3I3965 Close Zealand Pharma 0920 Zealand Pharma 1220
    Zealand Pharma 1503

    Would you like to stay up to date with Zealand news?

    Join our email list to receive company announcements and press releases directly to your inbox.

    Subscribe to news